Portal Hypertension Market to Benefit from Several Promising Drug Candidates in Pipeline

San Francisco, California, November 06, 2018: According to a recent market research report by TMR Research, The global market for portal hypertension is likely to witness a promising upward trajectory over the period between 2017 and 2025, driven chiefly to the rising global prevalence of liver cirrhosis, which is one of the leading causes of portal hypertension and other hepatic diseases. The report is titled “Portal Hypertension Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025.”

Get Sample Copy of this Report @ 


The market presently has a limited set of treatment options owing to the dearth of specialized drugs for the treatment of the condition. The market is currently being ruled by generic drugs, including somatostatin and its analogues, beta blockers, and vasopressin and its analogues. This hints at the lucrative growth opportunities that companies have in the field with effective R&D activities.

The market has seen a vast rise in drugs entering the clinical trial phases and is reaching a point of evolution. Noteworthy candidates that are presently in the phase III clinical trial are Sapropterin, Udenafil, and Octreolin. When these drugs are launched and approved, they will have the chance of acquiring a substantial share in the global portal hypertension market in the next few years.

Read Comprehensive Overview of Report @


Based on diagnosis, Duplex Doppler ultrasonography has remained one of the most promising candidate in the market owing to its high rate of efficiency in diagnosing portal hypertension. Besides, technologies such as computed tomography, angioplasty, scanning, magnetic resonance imaging, and bleeding scan are also used for the diagnosis of the condition.

Some of the leading companies operating in the global portal hypertension market are Dong-A Socio Holdings Co Ltd., Ono Pharmaceutical Co., Ltd., Genextra S.p.a., Debiovision, Inc., Novartis AG, Aptalis Pharma Inc., United Therapeutics Corporation, Govind Ballabh Pant Hospital, Gilead Sciences, Inc., Dr. Falk Pharma GmbH, and Chiasma, Inc.

Sapropterin, Octreolin, Udenafil Key Portal Hypertension Pipeline Drugs

San Francisco, California, July 14, 2017: TMR Research speaks on the presently burgeoning market for portal hypertension treatment options, in “Portal Hypertension Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025.” Portal hypertension refers to the increase in blood pressure in the portal venous system, a condition that can create several complications in a patient, ranging from chronic pain and discomfort to swollen veins and rupturing, eventually leading to life-threatening problems.

The increasing number of the elderly patients, coupled with the increasingly stressful and sedentary urban lifestyle, are giving way to a growth in the number of patients suffering from portal hypertension. Unfortunately, the current scenario in the global portal hypertension market does not have many players offering effective specialized drugs that are approved for use. This leads to a large chunk of revenue from the market to be taken up by generics, including vasopressin analogues, beta blockers, and somatostatin analogues.

Over the coming years, however, there is likely to be a spike in demand for specialized treatments, primarily due to the growing record of patients diagnosed with liver cirrhosis. Liver cirrhosis is considered to be a key causal factor for portal hypertension as well as several hepatic problems.

In terms of diagnosis, the global portal hypertension market is currently dominated by the Duplex Doppler Ultrasonography procedure. This procedure is likely to witness a surge in demand over the coming years, while it is currently highly recommended in use as an advanced imaging technique for portal hypertension diagnostics. Other diagnostic methods include MRI, CT scanning, and bleeding scanning. Each method provides efficient enough diagnostics, with the Duplex Doppler method showing several advantages over the others.

Nadolol and Propranolol are the two key medical treatment options available in the global portal hypertension market at the moment. Both are the key types of beta blockers being used in treatment. Other treatment options include common endoscopic therapies such as banding and sclerotherapy. Vasoactive agents, due to their capacity in cutting down in-variceal bleeding, are highly preferred in the treatment of portal hypertension by helping the body lower its blood pressure. For more serious cases, ectreotide and somatostatin, two key vasoconstrictors, are used globally.

The pipeline analysis of the market consists of products currently under the phase III of clinical trials. Some of the most notable candidates are Sapropterin (tetrahydrobiopterin), Octreolin (octreotide), and Udenafil (DA-8519). Once approved, the launch of these drugs could generate high revenue for the market.

Some of the prominent players in the global portal hypertension market are Ono Pharmaceutical Co., Ltd., United Therapeutics Corporation, Chiasma, Inc., Genextra S.p.a., Aptalis Pharma Inc., Gilead Sciences, Inc., Debiovision, Inc., Dong-A Socio Holdings Co Ltd., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, and Novartis AG.